Gastrointestinal Stromal Tumor (GIST) News 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Drug Trial Snapshot: AYVAKIT
AYVAKIT is used to treat adult patients with gastrointestinal stromal tumor (GIST) whose disease: is caused by certain abnormal platelet-derived growth factor receptor alpha (PDGFRA) genes and, cannot be surgically removed or, has spread throughout the body (metastatic GIST). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 24, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news
FDA approves the first targeted therapy to treat a rare mutation in patients with gastrointestinal stromal tumors
The U.S. Food and Drug Administration approved Ayvakit (avapritinib) for the treatment of adults with unresectable (unable to be removed with surgery) or metastatic (when cancer cells spread to other parts of the body) gastrointestinal stromal tumor (GIST) - a type of tumor that occurs in the gastrointestinal tract, (Source: World Pharma News)
Source: World Pharma News - January 10, 2020 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news
Ayvakit Approved to Treat GIST With PDGFRA Exon 18 Mutation
FRIDAY, Jan. 10, 2020 -- The kinase inhibitor Ayvakit (avapritinib) has been approved to treat adults with unresectable or metastatic gastrointestinal stromal tumors (GISTs) with a platelet-derived growth factor receptor alpha (PDGFRA) exon 18... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - January 10, 2020 Category: General Medicine Source Type: news
FDA Approves Avapritinib for Resectable or Metastatic Gastrointestinal Stromal Tumor
The FDA approved avapritinib for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumor harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations. (Source: CancerNetwork)
Source: CancerNetwork - January 10, 2020 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news
FDA Approves Avapritinib (Ayvakit) for GIST with Mutation FDA Approves Avapritinib (Ayvakit) for GIST with Mutation
The new product is indicated for use in gastrointestinal stromal tumors (GIST) that harbor a mutation, which renders these tumors resistant to standard therapy.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 10, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
FDA approves avapritinib for gastrointestinal stromal tumor with a rare mutation
On January 9, 2020, FDA approved avapritinib (AYVAKITTM, Blueprint Medicines Corporation) for adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including D842V mutations. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 9, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news
FDA approves the first targeted therapy to treat a rare mutation in patients with gastrointestinal stromal tumors
FDA approved Ayvakit (avapritinib) for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 9, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news
FDA Approves Ayvakit (avapritinib) for the Treatment of Adults with Unresectable or Metastatic PDGFRA Exon 18 Mutant Gastrointestinal Stromal Tumor
CAMBRIDGE, Mass., Jan. 9, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that the U.S. Food and Drug... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - January 9, 2020 Category: Drugs & Pharmacology Source Type: news
Deciphera Pharmaceuticals Announces Submission of New Drug Application to U.S. FDA for Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors
WALTHAM, Mass.--(BUSINESS WIRE)--Dec. 16, 2019-- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ripretinib, the... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - December 16, 2019 Category: Drugs & Pharmacology Source Type: news
NIOSH Asking for National Mesothelioma Registry Input
The National Institute for Occupational Safety and Health has begun soliciting public input on the feasibility of establishing a mesothelioma registry.
NIOSH is encouraging doctors, nurses, patients, families and patient advocates to provide recommendations on data collection, enrollment, registry maintenance, confidentiality and the overall usefulness of such a tool if enacted.
Comments must be received by July 8, 2019.
“NIOSH has a strong interest in preventing mesothelioma and helping people with the disease,” according to its outreach effort on Regulations.gov. “Mesothelioma treatments are limited, and survival i...
Source: Asbestos and Mesothelioma News - May 1, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news
Congress Funds Feasibility Study for Mesothelioma Patient Registry
The National Institute for Occupational Safety and Health will oversee a study in 2019 to determine the feasibility of establishing the first national mesothelioma patient registry.
The $100,000 feasibility study was part of the $1.2 million Congress allocated in 2019 to the Centers of Disease Control and Prevention for mesothelioma research.
The bulk of the funding goes toward the National Mesothelioma Virtual Bank, which is a biospecimen registry first established in 2006.
It is the only federally funded program designed exclusively for the research of mesothelioma, the rare and aggressive cancer caused by asbestos expos...
Source: Asbestos and Mesothelioma News - January 15, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news
CHLA participates in novel cancer consortium announced at the Biden Cancer Summit
(Children's Hospital Los Angeles) Former Vice President Joe Biden and Dr. Jill Biden hosted the national Biden Cancer Summit, on Sept. 21, to highlight the urgent need for creating transformative approaches to cancer prevention, research and treatment. One of the new initiatives announced was the formation of a consortium to advance research into effective treatments for patients with a type of cancer called Gastrointestinal Stromal Tumor (GIST) who do not respond to current standard treatments. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 21, 2018 Category: International Medicine & Public Health Source Type: news
Gastrointestinal Stromal Tumors
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - June 27, 2018 Category: General Medicine Source Type: news
Gastrointestinal Stromal Tumors in Children
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - November 8, 2017 Category: General Medicine Source Type: news
GIST tumors linked to NF1 mutations, genetic testing needed
(University of California - San Diego) Researchers at UC San Diego Moores Cancer Center, with colleagues from Memorial Sloan Kettering Cancer Center and Fox Chase Cancer Center, have determined that a specific region of the small bowel, called the duodenal-jejunal flexure or DJF, shows a high frequency of gastrointestinal stromal tumors (GISTs) with mutations of the NF1 gene. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 18, 2017 Category: International Medicine & Public Health Source Type: news
